Lv1
64 积分 2025-03-19 加入
Toripalimab plus bevacizumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma (HEPATORCH): a randomised, open-label, phase 3 trial
3小时前
待确认
Vascular invasion in hepatocellular carcinoma: prevalence, determinants and prognostic impact
5小时前
已完结
Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma
7小时前
已完结
Anlotinib plus penpulimab versus sorafenib in the first-line treatment of unresectable hepatocellular carcinoma (APOLLO): a randomised, controlled, phase 3 trial
10小时前
已完结
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
11小时前
已完结
Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study
11小时前
已完结
Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study
11小时前
已完结
Expanding control of the tumor cell cycle with a CDK2/4/6 inhibitor
1个月前
已完结
Treatment consequence and adverse events of cyclin-dependent kinase 4/6 inhibitors on patients with hormone receptor-positive, HER2-negative metastatic breast cancer: a systematic review and meta-analysis
1个月前
已完结
Discovery and preclinical evaluations of TQB3616, a novel CDK4-biased inhibitor
1个月前
已完结
皖公网安备34019202002308
